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Abstract Catheters are widely used for vascular access
and for the administration of drugs or fluids in critically ill
patients. This exposes patients to an infection risk. Tega-
derm chlorhexidine gluconate (CHG) (developed by 3M)—
a transparent securement dressing—covers and protects
catheter sites and secures devices to the skin. It comprises a
transparent adhesive dressing to act as a barrier against
external contamination and an integrated gel pad contain-
ing an antiseptic agent. The Medical Technologies Advi-
sory Committee (MTAC) at the National Institute for
Health and Care Excellence (NICE) selected Tegaderm
CHG for evaluation. One study was identified by the
sponsor as relevant to the decision problem. From this, the
sponsor concluded that compared with standard dressings,
Tegaderm CHG is associated with lower rates of catheter-
related infection, but increased dermatitis incidence. The
External Assessment Centre (EAC) identified four paired
comparative studies between Tegaderm CHG, other CHG
dressings or standard dressings. The EAC agreed with the
sponsor’s conclusion, finding that CHG dressings reduce
infections compared with standard dressings. The sponsor
constructed a de novo costing model. Tegaderm CHG
generated cost savings of £77.26 per patient compared with
standard dressings and was cost saving in 98.5 % of a
sample of sets of inputs (2013 prices). The EAC critiqued
and updated the model’s inputs, yielding similar results to
those the sponsor estimate. The MTAC reviewed the evi-
dence and decided to support the case for adoption, issuing
a positive draft recommendation. After a public consulta-
tion, NICE published this as Medical Technology Guid-
ance 25.
Key Points for Decision Makers
The case for adopting the 3M Tegaderm
chlorhexidine gluconate (CHG) IV securement
dressing for central venous and arterial catheter
insertion sites is supported by the evidence. This
technology allows observation and provides
antiseptic coverage of the catheter insertion site. It
reduces catheter-related bloodstream infections and
local site infections compared with semipermeable
transparent (standard) dressings. It can be used with
existing care bundles.
The 3M Tegaderm CHG IV securement dressing
should be considered for use in critically ill adults
who need a central venous or arterial catheter in
intensive care or high-dependency units.
The estimated cost saving from using Tegaderm
CHG instead of a standard dressing is £73 per
patient. If this became standard practice, it has the
potential to save the National Health Service (NHS)
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1 Introduction
The National Institute for Health and Care Excellence
(NICE) produces evidence-based medical technologies
guidance to evaluate and, where appropriate, encourage
adoption of novel and innovative medical devices and
diagnostics within the National Health Service (NHS) in
England. Sponsors of potentially eligible technologies
notify their products to NICE’s Medical Technologies
Evaluation Programme (MTEP). Technologies are selected
for evaluation as NICE medical technologies guidance by
the MTEP if they have the potential to offer clinical ben-
efits to patients and the NHS, and/or to reduce costs,
compared with standard care.
Guidance is developed by the Medical Technologies
Advisory Committee (MTAC) after the clinical and
economic evidence submitted by the sponsor is
assessed independently by an External Assessment
Centre (EAC) and following a public consultation
period. Devices and diagnostic tools with different, or
complex, value propositions can be routed for evalu-
ation through other NICE programmes, including the
Diagnostics Assessment Programme. Campbell and
Campbell [2] described the MTEP’s methodology in
more detail.
In July 2015, NICE issued final guidance on the
Tegaderm chlorhexidine gluconate (CHG) dressing for
use in intensive care settings with patients requiring
an arterial or central venous catheter (CVC). Tega-
derm CHG—a transparent securement dressing—is
used to cover and protect catheter sites and secure
devices to the skin. The dressing, developed by 3M,
comprises a transparent adhesive dressing and an
integrated gel pad. The gel pad absorbs fluid and
contains an antiseptic agent consisting of 2 % CHG,
and the transparent adhesive dressing acts as a barrier
against external contamination, protecting the catheter
insertion site [3]. The EAC critiquing the evidence
was the Newcastle upon Tyne Hospitals NHS Foun-
dation Trust and York Health Economics Consortium
partnership. Clinical experts, identified using NICE’s
published processes, provided advice to the EAC and
MTAC.
This article is one of a series of Medical Technol-
ogy Guidance summaries being published in Applied
Health Economics and Health policy. It summarises
the sponsor’s submission on Tegaderm CHG’s clinical
and cost effectiveness, provides an overview of the
EAC’s report and subsequent development of the
NICE guidance. Full documentation of the process,
supporting evidence and the final guidance is on the
NICE website [1].
2 Background to the Indications and Device
Critically ill adult patients are usually treated in intensive
care units (ICUs) or high-dependency units (HDUs), to
support the functioning of at least one organ. In England in
2012/2013, there were 237,710 adult ICU episodes with
organ support provided for a mean of 4 days [4]. Clinicians
managing critically ill adult patients usually require vas-
cular access for haemodynamic monitoring and/or the
administration of medication or fluids, which is achieved
through an arterial catheter or CVC. At least 78 % of
critically ill patients have some form of CVC [5].
The susceptibility of infection in critically ill patients is
higher than the general population in part because ICU
patients are exposed to specific risk factors, including
invasive treatments and monitoring. Infections in critically
ill patients can be further complicated because clinical
signs may be masked by signs of co-existing disease [5].
Infections occur after catheters become colonised by
microorganisms, which can take place during either
catheter insertion or routine care. Colonisation can lead to
catheter-related bloodstream infection (CRBSI) in an esti-
mated 1.48 of every 1000 catheter days [6]. CRBSI occurs
when bacteria or fungi present following colonisation,
migrate along the extraluminal catheter surface and into the
bloodstream [7]. This can lead to systemic infection, in turn
causing an immune response that can lead to septic shock
and multiple organ failure if undetected, increasing the risk
of death [8].
Measures to reduce the risk of CRBSI and local infec-
tions at the catheter entry site are recommended in NICE
guidelines on infection (Clinical Guideline 139). These
include:
• Decontaminating the skin at the insertion site with
CHG in 70 % alcohol before inserting a central
catheter.
• Using a sterile, transparent semipermeable membrane
dressing to cover the insertion site.
• Changing the transparent semipermeable membrane
dressing every 7 days, or sooner if the dressing is no
longer intact or moisture collects under it.
• During dressing changes, the CVC insertion site and
surrounding skin should be decontaminated, using
CHG in 70 % alcohol, and allowed to air dry [9].
Tegaderm CHG is an alternative to transparent
semipermeable membrane dressings (referred to as ‘stan-
dard dressings’ herein). Antiseptic coverage is delivered
through a CHG-impregnated gel incorporated into the
dressing, which is placed over the catheter insertion site,
and is intended to reduce skin and catheter colonisation,
and hence the incidence of CRBSI. The gel is transparent,
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meaning the insertion site can be observed continually [3].
Tegaderm CHG was claimed to prevent catheter-related
infection (CRI), thus reducing the risk of mortality, length
of stay in ICU and costs associated with infection.
Tegaderm CHG was considered by the MTAC as an
alternative to standard dressings used alone or in con-
junction with a CHG sponge, as defined in the scope pro-
duced by NICE [10]. This describes the decision problem
to be addressed by the sponsor and EAC and is described
here in more detail.
3 Decision Problem (Scope)
3.1 Population
The population described in the scope was critically ill
adult patients in ICUs or HDUs who require a CVC or
arterial catheter. Although Tegaderm CHG is suitable for
use in infants aged 2 months or above [3], children were
outside of the scope due to a lack of evidence relating to
the efficacy and safety of Tegaderm CHG in this subgroup.
3.2 Intervention (Tegaderm CHG)
The intervention specified in the scope was swabbing with
2 % CHG in alcohol and Tegaderm CHG intravenous (IV)
securement dressing. Tegaderm CHG is available in four
sizes, with the most commonly used being 8.5 9 11.5 cm,
containing 45 mg of CHG [3]. All four sizes of the dressing
are CE marked.
3.3 Comparator (Current Practice)
Two comparators were specified in the scope:
• Swabbing with 2 % CHG in alcohol, followed by
sterile semipermeable transparent dressing (standard
dressing).
• Swabbing with 2 % CHG in alcohol, followed by
CHG-impregnated dressing (CHG sponge).
The CHG sponge comprises a standard dressing, toge-
ther with a CHG-impregnated patch (marketed under the
product name ‘Biopatch’). Unlike Tegaderm CHG, it is not
a single item, is not transparent and contains 18 % dry
CHG that is released by humidity from the skin.
3.4 Outcomes
The sponsor addressed six of the eight specified clinical
outcomes for Tegaderm CHG and standard dressings,
being CRBSI, skin and catheter colonisation, local site
infection, dermatitis, adverse events and length of stay.
Skin colonisation was the only outcome considered for the
CHG sponge. The sponsor did not identify evidence on
quality of life or mortality resulting from CRI.
CRBSI can be defined as a combination of one or more
of the following, with no other infectious focus explaining
the positive blood cultures:
• Positive peripheral blood cultures sampled immediately
before or within 48 h after catheter removal.
• A positive quantitative catheter-tip culture.
• A blood-culture differential time-to-positivity of 2 h or
more [11, 12].
Adverse events resulting from the use of both Tegaderm
CHG and comparator dressings, including skin reactions or
dermatitis, are described within clinical studies.
4 Review of Clinical and Economic Evidence
Clinical and economic evidence, including a de novo cost
model, was submitted by the sponsor in line with the
process set out by NICE [13]. The EAC critically appraised
the submission and costing model against the scope. Sec-
tion 4.1 summarises the clinical evidence submitted, the
EAC’s critique and the EAC’s new work. Section 4.2
provides the same detail for the economic evidence.
4.1 Clinical Effectiveness Evidence
4.1.1 Sponsor’s Review of Clinical Effectiveness Evidence
The sponsor searched for published clinical evidence relat-
ing to the decision problem. Included studies compared
Tegaderm CHG with standard dressings or CHG sponges.
The sponsor included one study [11] which reported a
multicentre randomised control trial (RCT) of 1879 patients
using 4163 catheters conducted between May 2010 and July
2011. Adult patients requiring intravascular access in 12
ICUs in hospitals in France were randomised to one of three
groups: Tegaderm CHG, standard dressing (Tegaderm
Transparent Film Dressing) or highly adhesive dressing
(Tegaderm HP Transparent Film Dressing). Assessors of
suspected infection were blinded to dressing type. Patients
had their skin prepared with alcohol-povidone iodine or
alcohol-CHG (0.5 %). Dressings were replaced after 24 h
and then every 3–7 days according to local protocol, or as
required due to leaking or soiling. Patients with known
allergies to CHG or transparent dressings were excluded.
Results were reported up to 48 h after ICU discharge [11].
The sponsor appropriately critically appraised its included
study [11], finding it to be at low risk of bias.
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An accurate description of the results reported in the
RCT was provided by the sponsor. This included statistical
comparisons between Tegaderm CHG and a combined
control of standard dressings and highly adhesive dressings
in line with those used in the study. Tegaderm CHG was
reported to significantly reduce CRBSI compared with non-
CHG dressings {hazard ratio (HR) = 0.402 [95 % confi-
dence interval (CI) 0.186–0.868]; p = 0.02} and signifi-
cantly reduce catheter colonisation [HR = 0.412 (95 % CI
0.306–0.556); p\ 0.0001]. The length of stay in ICU was
similar between groups (9 or 10 days). Severe contact
dermatitis requiring removal of dressings occurred signif-
icantly more in the Tegaderm CHG group, compared with
the non-CHG group (Tegaderm CHG = 1.1 % of cathe-
ters; standard dressing = 0.1 %; highly adhesive dress-
ing = 0.5 %; p\ 0.0001). No systemic adverse reactions
were reported.
The sponsor provided US Food and Drug Administra-
tion (FDA) Manufacturer and User Facility Device Expe-
rience (MAUDE) and UK Medicines and Healthcare
Products Regulatory Agency (MHRA) reports for Tega-
derm CHG. The sponsor identified 109 FDA MAUDE
reports, often describing local reactions occurring within
48 h of dressing application. Reactions included redness
and irritation that was sometimes severe. In many cases,
adverse reactions were self-healing. However, there were
seven reports of an eschar (dead tissue) at the dressing site.
The sponsor reported, based on a study in healthy vol-
unteers, that reduction in skin colonisation is similar
between Tegaderm CHG and CHG sponges [14]. Further,
the sponsor provided information on the relative ease of
use and performance of the three dressings based on three
studies that were identified during its clinical evidence
review, but did not meet the inclusion criteria [15–17]. The
patients in these studies were not all critically ill. Nurses
within all studies reported statistically significantly higher
satisfaction with Tegaderm CHG than standard dressings
[15–17].
The sponsor concluded that the evidence shows, com-
pared with standard dressings, Tegaderm CHG is associ-
ated with lower rates of CRBSI and catheter colonisation,
but increased incidence of dermatitis. The sponsor stated
that the results of its included study are likely to be gen-
eralisable to other settings with similar catheter care and
dressing protocols.
4.1.2 Critique of Clinical Effectiveness Evidence
The EAC critiqued the sponsor’s literature search, evidence
selection and quality assessment of included studies.
Replication of the sponsor’s searches obtained a similar
yield of search results. The study selection criteria
employed by the sponsor included only comparative
studies containing a Tegaderm CHG arm. Although con-
sistent with the decision problem issued by NICE, this
meant that no CHG sponge evidence was included. The
EAC reviewed the critical appraisal and results reported by
the sponsor [11], finding these to be detailed and accurate.
The EAC undertook its own literature search and
included studies comparing any two of the three dressing
types in order to identify relevant studies of CHG sponges
to inform the comparator. A search comprising three con-
cepts (catheters, dressings and CHG) was carried out on a
number of databases, including MEDLINE, Embase and
the Cochrane Library, and the grey literature (strategies are
described in the EAC assessment report [1]).
Included studies were limited to prospective compara-
tive studies of critically ill adult patients in ICUs or HDUs.
The selection criteria were in line with the scope issued by
NICE, with the exception of the skin preparation solution.
The scope specifies that prior to catheter insertion, skin
should be prepared with 2 % CHG in alcohol solution as
defined in the NICE clinical guideline on infection [9]. In
order to maximise sensitivity, the skin preparation solution
was not specified within the selection criteria.
The PRISMA diagram [18] (Fig. 1) shows the number
of papers retrieved and excluded following dual selection
by two independent reviewers, together with reason for
exclusion. The EAC included four studies; two compared
Tegaderm CHG with standard dressings [11, 19] and two
compared CHG sponges with standard dressings [12, 20].
One of the two Tegaderm CHG studies was presented as a
poster after the sponsor’s clinical evidence submission
[19]. The studies comprised the following number of
patients: N = 1879 [11]; N = 1653 [12]; N = 273 [19]
and N = 33 [20]. Three studies were published RCTs [11,
12, 20], and the remaining one study was a comparative
observational study [19]. Two of the three RCTs recruited
sufficient patient numbers to achieve 80 % statistical
power [11, 12], whilst the third study was underpowered
because of limited resources precluding the ability to
recruit the number of patients required to achieve statistical
significance [20]. The study reporting skin colonisation in
healthy volunteers was excluded by the EAC given no
critically ill patients were included [14].
Data from the included studies were extracted by one
reviewer and checked by a second. There were no signifi-
cant differences in the baseline characteristics of patients in
each group within each study. All four studies recruited
critically ill adult patients requiring intravascular access
within an ICU or critical care unit setting. CVCs were
included in all four studies, and arterial catheters were also
included in two of the three RCTs [11, 12]. The same two
studies excluded patients with a known allergy to CHG or
transparent dressings and reported that microbiologists
processing the skin and catheter cultures were blinded to
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treatment group [11, 12]. The remaining two studies did
not report exclusion criteria or blinding [19, 20].
Patients were followed up until catheter removal in two
studies [11, 12], and for 48 h after ICU discharge in the
remaining two studies [19, 20]. Variation existed in the
antiseptic skin preparation solution used. Skin preparation
with 2 % CHG in alcohol is in line with current NICE
guidelines [9], but was only used in one study [19].
Dressings were reported to be changed and attended to with
CHG in alcohol every fifth day in one study [20]. In two
studies dressings were changed after 24 h and then every 3
or 7 days, depending on randomisation or local hospital
protocol. Where dressings were soiled or leaking, they
were changed immediately [11, 12]. The final study did not
report the dressing change protocol [19].
Appraisals of the EAC’s four included studies are
reported in Table 1. Quality assessment using the checklist
provided in the MTEP sponsor submission template was
undertaken for three studies [11, 12, 20], but was not
possible for the study published as a conference poster
[15], because of limited information. Two of the three
RCTs were well conducted and judged to be at low risk of
bias, with the only concern being that no reason was pro-
vided for the exclusion of around 150 patients from the two
studies (n = 156 [11] and n = 147 [12]). If these patients
were inherently different to those included, there is risk of
bias. The third RCT [20] provided insufficient information
relating to the methodology to rule out bias.
The sponsor’s results included tests for differences in
outcomes between Tegaderm CHG and a combined control
of standard dressings and highly adhesive dressings. The
sponsor advised that Tegaderm highly adhesive dressings
(Tegaderm HP Transparent Film Dressing) are not used
within England, but are standard care within France where
Fig. 1 PRISMA flow diagram
showing clinical studies
assessed during the External
Assessment Centre review
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the study was set. The results comparing Tegaderm CHG
with standard dressings have greater applicability to the
decision problem than those including highly adhesive
dressings. However, the EAC noted many of the compar-
isons were only between dressings containing CHG versus
dressings not containing CHG.
The results of the EAC’s four included studies [11, 12,
19, 20] are provided in Table 2. Both studies by Timsit
et al. reported a statistically significant decrease (at
p\ 0.05) in CRBSI with CHG-impregnated dressings
(Tegaderm CHG or CHG sponge) [11, 12].
Catheter colonisation rates were reported in all studies
[11, 12, 19, 20], and skin colonisation rates were reported
in one study [19]. Both studies comparing Tegaderm CHG
to standard dressings reported lower catheter colonisation
rates. Timsit et al. [11] reported a lower incidence of
catheter colonisations with Tegaderm CHG than standard
dressings of 9.6 versus 4.3 per 1000 catheter days
(p\ 0.0001 for the combined control group). Karpanen
et al. [19] reported a lower CVC intradermal section
colonisation incidence (p = 0.037) and a lower incidence
of positive CVC tip colonisation (p\ 0.05) with Tegaderm
CHG. Timsit et al. [12] found catheter colonisation rates to
be lower in the CHG sponge group compared with standard
dressing (6.3 per 1000 catheter days vs. 15.8 per 1000
catheter days, p\ 0.001). Roberts and Cheung [20]
reported a non-significant higher incidence of both catheter
and skin colonisation with CHG sponge compared with
standard dressings.
No systemic adverse reactions to CHG were reported in
any study [11, 12, 19, 20]; two studies explicitly stated no
systemic adverse reactions had occurred [11, 12]. Both
studies excluded patients with known allergies to CHG,
which may limit the generalisability of adverse reaction
results to the NHS. Severe contact dermatitis requiring
removal of the dressing was reported in two studies [11,
12]. In both studies, the incidence of dermatitis was higher
with CHG-impregnated dressings (p\ 0.0001 [11] and
p = not reported [12]).
The EAC analysed data from FDA MAUDE for Tega-
derm CHG and its comparators, finding that following
launch of an improved breathable version of Tegaderm
CHG (in 2010), the rate of reported adverse reactions had
fallen. Reports for both Tegaderm CHG and CHG sponge
(specifically Biopatch) were similar in terms of the types
and volume of reactions being described: largely mild, self-
healing skin reactions requiring removal of the dressing.
The EAC validated the information provided by the
sponsor on the relative ease of use and performance of
Tegaderm CHG through targeted searching and seeking
expert opinion. Evidence from three US studies of nurses
managing non-critically ill patients reported Tegaderm
CHG is rated more favourable to use than CHG sponges
(p\ 0.05) in terms of ease of application and removal,
ability to see IV site and ease of training [21–23]. There
were mixed results in terms of nurse satisfaction with ease
of correct application, transparency (site visibility), ease of
dressing removal and patient discomfort. However, dif-
ferences rarely reached significance [21–23]. Evidence
from three studies comparing Tegaderm CHG to standard
dressings found nurses to be significantly more satisfied
with Tegaderm CHG (at p\ 0.05) as it provided more
Table 1 Summary of critical appraisal in relation to decision problem






Weaknesses in a number of domains were unlikely
to introduce bias
Treatment regime and patient
characteristics are partially
applicable to scope
High, most relevant and
highest quality study
on Tegaderm CHG
Timsit et al., CHG
sponge vs. standard
dressing [12]
Weaknesses in a number of domains were unlikely
to introduce bias
Treatment regime and patient
characteristics are partially
applicable to scope







Generally poor across all domains and poorly
reported. Potential for:
Selection bias as randomisation method not
described
Performance bias from limited information on
participants
Detection bias as no blinding was reported
Treatment regime is partially








Certain weaknesses noted, e.g. observational so no
randomisation. Overall, difficult to assess as
results are from a conference poster only
NHS treatment regime is applicable
to scope. Lack of information on
patient characteristics
Medium
CHG chlorhexidine gluconate, NHS National Health Service
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satisfactory securement and was easier to apply [15–17].
Expert opinion supported the view that Tegaderm CHG is
easier to use than CHG sponges and is at least as easy to
use as standard dressings.
No evidence was identified relating to mortality from
CRI, local site infections or quality of life. Clinical experts
advised that CRBSI can have a devastating impact on
mortality and quality of life.
4.1.3 New Work Undertaken by EAC Relating to Clinical
Evidence
The EAC performed a Z test to estimate whether the
CRBSI rate reported for Tegaderm CHG was significantly
different to that reported for the CHG sponge. The total
number of catheter days for each treatment group was
obtained from the study authors in order to conduct the
Z test [11, 12]. A score of 0.56 was obtained, with a p value
of 0.58. Therefore, no statistically significant difference is
estimated in the CRBSI rate between Tegaderm CHG and
the CHG sponge, suggesting that where baseline CRBSI
rates are at 1.3 per 1000 catheter days (as in the two RCTs
by Timsit et al. [11, 12]), both Tegaderm CHG and CHG-
impregnated sponges are effective in reducing CRBSI.
There is insufficient evidence to demonstrate that one is
more effective than the other.
4.1.4 Conclusions from Clinical Effectiveness Evidence
The EAC did not identify any evidence to suggest that the
conclusions drawn by the sponsor are invalid. Furthermore,
consideration of studies comparing CHG sponges to stan-
dard dressings suggested that the rates of CRBSI and sur-
rogate measures of infection, such as catheter colonisation,
are likely to be similar with CHG sponges and Tegaderm
CHG. The EAC concluded that both types of CHG-im-
pregnated dressings (Tegaderm CHG or CHG-impregnated
sponge) lead to lower rates of CRBSI and catheter
colonisation than standard dressings. There is a higher risk
of dermatitis with both Tegaderm CHG and CHG sponges
than with standard dressings, although this risk has
declined with the modified Tegaderm CHG product. Users
of the dressings reported that Tegaderm CHG is at least as
easy to use as standard dressings and easier to use than the
CHG sponge due to its transparency and all-in-one
component.
4.2 Economic Evidence
4.2.1 Sponsor’s Economic Submission
The sponsor undertook a search for economic studies of
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included by the sponsor that reported on the cost–benefits
of CHG sponges or antiseptic catheters compared with
standard care [24–28]. The sponsor drew no conclusions
from the economic evidence, other than that no UK-based
cost-effectiveness studies comparing Tegaderm CHG to
standard dressing were available.
A de novo decision analytic model was submitted by the
sponsor, which compared Tegaderm CHG and standard
dressings over a short time horizon, fromanNHS andPersonal
Social Services perspective, with prices expressed at 2013
levels. Given the lack of clinical evidence comparing Tega-
derm CHG with the CHG sponge, the sponsor excluded this
comparator from its analysis. A fully executable model was
created in Microsoft Excel. In the model, a simulated cohort
of critically ill patients requiring intravascular access received
a Tegaderm CHG dressing or a standard dressing. Patients
within the model were at risk of CRBSI, local site infection or
dermatitis (Fig. 2). A baseline risk of each complication was
used for standard dressings and relative risks applied to these
for Tegaderm CHG. The sponsor’s base case results were
probabilistic, based on 1000 iterations of the model.
The model was populated using data identified from the
sponsor’s clinical evidence review of the effectiveness of
Tegaderm CHG on CRBSI, local site infection and
dermatitis [11]. The economic literature review identified
studies with evidence of baseline risk of complications,
cost and resource use inputs [25, 26, 28], baseline CRBSI
risk [6] and the number of dressings required [3]. All model
input parameters are shown in Table 3.
Probabilistic results from the sponsor’s economic model
showed Tegaderm CHG generates cost savings of £77.26
per patient compared with standard care. This was based on
costs of £99.63 per patient using Tegaderm CHG and
£176.89 per patient using standard dressings. Probabilistic
sensitivity analysis (PSA) was conducted using the ranges
and distributions shown in Table 3. Tegaderm CHG was
found to be cost saving in 98.5 % of model runs. Uni-
variate sensitivity analyses were conducted around the two
key drivers of the results: baseline risk of CRBSI (0.5–5.5
infections per 1000 catheter days) and the cost of CRBSI
(£5000–15,000). Tegaderm CHG remained cost saving
compared with standard dressings for all values examined.
The results of the de novo economic modelling led the
sponsor to conclude that the potential cost savings gener-
ated by Tegaderm CHG compared with standard dressings
are robust to the uncertainties identified, particularly the
rate of CRBSI and its associated costs. These were also
consistent with cost savings generated by other
Fig. 2 Economic model
structure
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antimicrobial devices used to prevent CRI, from the liter-
ature [24–28].
4.2.2 Critique of Economic Evidence
The EAC was unable to replicate the sponsor’s literature
search for economic evidence as insufficient information
was provided. The EAC excluded the five studies included
by the sponsor because none of these used Tegaderm CHG
as a comparator [24–28]. Rather, these studies all com-
pared the cost effectiveness of CHG sponges with standard
dressings.
TheEAC’s search for clinical evidence did not specify study
design; therefore, the results were sifted for any economic
studies relating to Tegaderm CHG. Four cost–benefit analyses,
published subsequent to the conduct of the sponsor’s literature
search, were included [29–32]. All were conference abstracts,
written by the same authors, using data from the Timsit et al.
[11] RCT. Each study used different economic model struc-
tures and/or reported different results, in order to assess the
cost–benefits of Tegaderm CHG compared with standard
dressings from a French healthcare system perspective. None
of the studies reported statistically significant differences in
outcomes between the comparators.
Table 3 Model input parameters used in sponsor’s economic model
Parameter Value, range and distribution Description
Clinical input parameters
Baseline CRBSI rate 1.48 per 1000 catheter days; normal distribution;
standard error = 0.074 (calculated in Excel sheet
as mean divided by 20)
Source was data reported in Matching Michigan study, based
on CRBSI rates reported in 97 % of English NHS ICUs [6]
Hazard ratio for CRBSI
with Tegaderm CHG
0.402; lognormal distribution; Alpha = -0.911
(calculated in Excel sheet as log mean);
Beta = -0.393 (source unclear)
Source was the RCT identified in the sponsor’s clinical




0.1 per patient; normal distribution; standard
error = 0.01 (calculated in Excel sheet as mean
divided by 10)
Source was a cost–benefit analysis identified in the sponsor’s
cost-effectiveness review [28]. The original source was a
small US RCT published in 1996 [34]
Hazard ratio for localI
site infection withI
Tegaderm CHG
0.402; lognormal distribution; Alpha = -0.911
(calculated in Excel sheet as log mean);
Beta = -0.393 (source unclear)
Assumed to be the same as the hazard ratio for CRBSI [11]
and applied to baseline risk
Baseline dermatitis risk 0.0026 per catheter; normal distribution; standard
error = 0.00026 (calculated in Excel sheet as mean
divided by 10)
Source was a cost–benefit analysis identified in the sponsor’s
cost-effectiveness review [26]. The original source was the





4.4; lognormal distribution; Alpha = 18.034
(calculated in Excel sheet as log mean);
Beta = -0.393 (source unclear)
Relative risk was taken from the RCT identified in the
sponsor’s clinical review [11] and applied to the baseline
risk
Cost and resource use input parameters
Cost of CRBSI £9,990; Gamma distribution; Alpha = 198
(calculated in Excel sheet as mean divided by
Beta); Beta = 50 (assumption)
Source was a 2008 health technology assessment identified in
the sponsor’s cost-effectiveness review [25] and validated
using expert advice by the sponsor
Cost of dermatitis £150; Gamma distribution; Alpha = 30 (calculated
in Excel sheet as mean divided by Beta);
Beta = 5 (assumption)
Source was a cost–benefit analysis identified from the
sponsor’s cost-effectiveness review [26]. The cost includes
replacement of the catheter
Cost of local siteI
infection
£250; Gamma distribution; Alpha = 50 (calculated
in Excel sheet as mean divided by Beta);
Beta = 5 (assumption)
Source was a study identified in the sponsor’s cost-
effectiveness analysis [28]. The original source of the cost
provided no additional information [39]
Cost of TegadermI
CHG
£6.21; value is fixed Published price of the most commonly used size of dressing:
8.5 cm 9 11.5 cm (catalogue number 1657R)
Cost of standardI
dressing
£1.34; value is fixed The sponsor obtained this cost from their own prices for
Tegaderm IV catalogue number 1635
Number of days withI
catheter
10 days; normal distribution; standard
error = 2 days (calculated in Excel sheet as mean
divided by 5)
Source was a study identified in the sponsor’s cost-
effectiveness analysis [28]. The original source of the value
provided no additional information [40]
Number of dressings 3; normal distribution; standard error = 0.3
(calculated in Excel sheet as mean divided by 10)
Estimate was a conservative assumption based on to
Tegaderm CHG Instructions for Use and expert opinion
CHG chlorhexidine gluconate, CRBSI catheter-related bloodstream infection, ICU intensive care unit, NHS National Health Service, RCT
randomised control trial
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The EAC judged as accurate the sponsor’s conclusion
that no UK-based cost-effectiveness studies comparing
Tegaderm CHG to standard dressing were available. Thus,
it was appropriate for the sponsor to build a de novo eco-
nomic model. The EAC replicated the sponsor’s calcula-
tions in order to confirm their accuracy, correcting a minor
error relating to the dermatitis rate in both arms of the
model. A number of structural assumptions were identified
by the EAC; these simplifying assumptions were necessary
given the data available and were unlikely to have intro-
duced material bias. The EAC judged, after seeking advice
from clinical experts, that the structure of the model, whilst
relatively simple, captured the key differences between
Tegaderm CHG and standard dressings. Ideally, however,
the model would also have included the third dressing type,
the CHG sponge. The sponsor judged that the lack of
comparative data between Tegaderm CHG and CHG
sponge precluded the inclusion of this comparison in its
cost-effectiveness analysis. The exclusion of this dressing
from any cost analysis was the key weakness of the
sponsor’s economic submission.
All model inputs were validated by the EAC using
expert advice and the literature. The EAC made changes to
a number of model inputs, as shown in Table 4. Both the
baseline rate and relative risk of dermatitis were amended,
such that the baseline rate used was from the standard
dressing arm of an RCT [11] and the relative risk was
assumed to be 1 given the low rate of dermatitis with the
new design of Tegaderm CHG. The baseline local site
infection rate was updated to the 2013 rate from NHS ICUs
in Wales [33], rather than the 1996 value used by the
sponsor [34]. The cost of dermatitis and local site infec-
tions were lowered based on expert advice and the costs of
both dressings updated to NHS Supply Chain prices [35].
In addition, the EAC amended distributions and ranges
around input parameters to those it deemed most appro-
priate (see Table 4).
Following these updates, the EAC re-ran the sponsors
model 10,000 times (based on the number of iterations
required for results to become stable). Tegaderm CHG
generated cost savings of £72.90 per patient compared with
standard dressings and was cost saving in 97.8 % of runs.
Univariate sensitivity analyses using the ranges specified
for each model input parameters did not change the
direction of the results.
4.2.3 New Work Undertaken by EAC Relating to Economic
Evidence
The EAC considered a scenario using an alternative base-
line CRBSI rate. The rate used in the sponsor’s and EAC’s
base case analyses of 1.48 CRBSI per 1000 catheter days
was taken from NHS ICUs in 2010, reported in the
Matching Michigan study [6]. Before and during this study,
infection rates trended downwards; thus the current CRBSI
rate may differ to that from 2010. In 2013, NHS Scotland
and NHS Wales reported annual confirmed CRBSI rates of
0.3 per 1000 catheter days (95 % CI 0.2–0.6) [36] and 0.19
per 1000 catheter days [33], respectively, although NHS
Scotland acknowledged that CRBSIs were potentially
underreported. This rate was considered in a scenario to
explore the impact on cost effectiveness in ICUs with low
CRBSI rates. In this scenario, Tegaderm CHG was cost
saving compared with standard dressings in 57.9 % of the
10,000 model iterations, generating an average saving of
£3.56 per patient. Univariate sensitivity analysis showed
that Tegaderm CHG became cost incurring where the HR
of CRBSI to standard dressing was 0.53 or above, or the
cost of each CRBSI was £8,000 or below.
The EAC considered the relative cost effects of Tega-
derm CHG and CHG sponges, agreeing with the sponsor
that the lack of comparative data between Tegaderm CHG
and CHG sponge makes an analysis difficult. However,
some exploratory analysis was conducted. The EAC con-
cluded that based on the available clinical evidence and the
Z score generated, there appeared to be no significant
differences in the clinical efficacy of the two CHG-im-
pregnated dressings. Clinical experts advised that the
resource implications of the two dressings are similar,
although potentially higher with the CHG sponge because
of its two-component nature. Therefore, it was assumed
that clinical efficacy and resource use between the two
dressings are essentially equivalent, enabling a cost-min-
imisation exercise to be conducted.
The NHS Supply Chain catalogue price for a CHG-
impregnated dressing (Biopatch) is £6.80 [35]. Adding a
standard dressing gives a combined cost of £8.13, around
£2 per dressing more than Tegaderm CHG. The sponsor
provided a lower cost for Biopatch of £5.16. Given that no
sales of Biopatch were made through NHS Supply Chain in
the two previous financial years, but clinicians advised they
use the dressing, it is likely that Trusts purchase the
dressing via other sources at a cheaper price than the NHS
Supply Chain listed price [35]. Using the £5.16 cost for
Biopatch results in a combined cost, with the standard
dressing, of £6.49 per dressing, slightly more expensive
than Tegaderm CHG (costing £6.26).
5 NICE Guidance
5.1 Provisional Recommendations
The evidence submitted by the sponsor and the EAC’s
critique of this evidence was presented to the MTAC who
provided draft recommendations relating to Tegaderm
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CHG following their meeting in February 2015. These
were as follows [37]:
1. The case for adopting the 3M Tegaderm CHG IV
securement dressing for central venous and arterial
catheter insertion sites is supported by the evidence. This
technology allows observation and provides antiseptic
coverage of the catheter insertion site, reducing catheter
related bloodstream infections and local site infections
compared with semipermeable transparent (standard)
dressings. It can be used with existing care bundles.
2. The 3M Tegaderm CHG IV securement dressing
should be considered for use in critically ill patients
who need a central venous or arterial catheter in
intensive care or high dependency units.
Table 4 Model input parameters used in EAC’s update of the sponsor’s economic model
Variable EAC point estimate Source EAC range and source
Baseline CRBSI rate English data (2010):
1.48 per 1000 catheter
days
Scottish data (2013):
0.3 per 1000 catheter
days
Bion et al. [6]
Scottish ICU report [36]
DSA: range = 0.2–1.75, lower CI from Scotland
and upper CI from Bion et al. [6, 36]
PSA: Gamma distribution. The PSA was run
twice, with English data and more recent
Scottish data
Range = 1.28–1.75, 95 % CI from Bion et al. [6]
Range = 0.2–0.6, 95 % CI from Scotland [36]
Hazard ratio for CRBSI
with Tegaderm CHG
0.402 Timsit et al. [11] DSA: range is equal to 95 % CI of 0.186–0.868
PSA: lognormal distribution, with range equal to
95 % CI of 0.186–0.868 [11]
Baseline local site infection
rate
0.14 per 1000 catheter
days
NHS Wales 2013 data [33] DSA: a range of 0–0.3 infections per 1000
catheter days
PSA: Gamma distribution, with an SE of 0.1
Hazard ratio for local site
infection with Tegaderm
CHG
0.402 Assumed to be equal to hazard
ratio for CRBSI from Timsit
et al. [11]
DSA: range equal to 95 % CI of 0.186–0.868
PSA: lognormal distribution, with range equal to
95 % CI of 0.186–0.868 [11]
Baseline dermatitis
probability
0.0021 Timsit et al. [11] DSA: a range of 0–0.01
PSA: Beta distribution was used, with Alpha = 1




1 Timsit et al. [11] DSA: a range of ± 100 % (0–2)
PSA: lognormal distribution, with an SE of 0.5
Cost of CRBSI £9990 Hockenhull et al. [25] DSA: a range of ± 50 % (£4950–14,850)
PSA: Gamma distribution, with an SE of £3000
Cost of dermatitis £6 Expert advice DSA: a range of ± 30 % (£4.10–7.80)
PSA: Gamma distribution, with an SE of £3
Cost of local site infection £100 Expert advice DSA: a range of ± 30 % (£70–130)
PSA: Gamma distribution, with an SE of £30
Number of days with
catheter (catheter dwell
time)
10 days Expert advice confirmation of Ho
and Litton [40]
DSA: a range of ± 50 % (5–15 days)
PSA: Gamma distribution, with an SE of 5 days
Number of dressings 3 Assumption (based on change of
dressing every 3–7 days)
DSA: a range of ± 66 % (1–5 dressings)
PSA: Gamma distribution, with an SE of 2
dressings
Cost of Tegaderm CHG £6.26 NHS Supply Chain. Weighted
average of dressing sizes [35]
This is fixed and not included in either the
deterministic or probabilistic analyses
Cost of standard dressing £1.54 NHS Supply Chain. Weighted
average of brands [35]
This is fixed and not included in either the
deterministic or probabilistic analyses
CHG chlorhexidine gluconate, CRBSI catheter-related bloodstream infection, CI confidence interval, DSA deterministic sensitivity analysis, EAC
External Assessment Centre, ICU intensive care unit, NHS National Health Service, PSA probabilistic sensitivity analysis, SE standard error
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3. The estimated cost saving from using a 3M Tegaderm
CHG IV securement dressing (Tegaderm CHG)
instead of a standard transparent semipermeable
dressing is £73 per patient. These estimates are based
on a baseline catheter-related bloodstream infection
rate of 1.48 per 1000 catheter days. Tegaderm CHG is
estimated to be cost neutral when the baseline catheter-
related bloodstream infection rate is 0.24 per 1000
catheter days, and cost incurring when the baseline rate
falls below that figure. Estimates of the benefiting
population vary from around 88,000 to 226,000
depending on whether adult ICU episodes longer than
48 hours requiring a central venous catheter, or all
adult ICU episodes requiring a central venous catheter,
are used. Based on these estimates, if the use of
Tegaderm CHG became standard practice, it has the
potential to save the English NHS between £6.2
million and £16.5 million each year, assuming the
baseline catheter related bloodstream infection rate is
1.48 per 1000 catheter days [37].
5.2 Consultation Response
During the consultation, NICE received 44 consultation
comments from seven consultees. Consequently, the NICE
draft guidance was updated to address these comments. A
description of central-line–associated bloodstream infec-
tion (CLABSI) was added, along with an explanation of its
association to CRBSI.
The epic3 guideline was used within the Tegaderm CHG
draft guidance to describe current best practice guidance
for preventing healthcare-associated infections in English
NHS hospitals [38]. The description of the evidence that
the epic3 guideline is based upon was expanded in the final
NICE guidance to include more detail on the quality of this
evidence. In regard to the evidence included in the spon-
sor’s submission, the guidance was updated to describe
where this submission deviated from the original scope; the
key deviation being the lack of comparison between
Tegaderm CHG and other CHG-impregnated dressings.
Other sections of the guideline were updated to describe
in more detail the benefits of visualising the catheter
insertion site and to clarify that the recommendations relate
to adults only. Minor revisions were made to other sections
to improve clarity.
There were no consultation comments about the esti-
mated potential population-level cost savings in draft rec-
ommendation 3; however, further work by the NICE
Resource Impact Assessment team resulted in revisions to
this section. In particular, there was a change to the esti-
mated uptake of the technology. The section is based on an
estimate of current use of 15 %, and assumes future uptake
at 80 %.
6 Key Challenges and Learning points
The key challenges faced by the EAC and the sponsor were
the lack of evidence comparing Tegaderm CHG with other
CHG-impregnated dressings and the generalisability of the
clinical evidence. As none of the clinical studies included
by the sponsor or identified by the EAC compared Tega-
derm CHG and other CHG-impregnated dressings, the
EAC had to rely on an informal indirect comparison of the
two dressings using the two RCTs published by Timsit
et al. [11, 12]. The similar inclusion criteria, outcome
measurement and patient characteristics between the two
studies aided confidence in the comparison [11, 12]. A
cost-minimisation exercise was conducted by the EAC to
compare Tegaderm CHG and other CHG-impregnated
dressings based upon the assumption of clinical equiva-
lence. This exercise provided an estimate of the relative
cost effectiveness of the two dressings. However, the lack
of comparative data prevented both the sponsor and EAC
conducting a robust cost-effectiveness comparison.
Three of the four clinical studies included by the EAC
were set outside the UK [11, 12, 20]. Catheter insertion site
care protocols and patients included within the studies
differed in part to those in the UK. The EAC assessed the
generalisability of the studies to the NHS by consulting
with clinical experts and making comparisons with English
clinical guidelines. Two of the three studies were judged to
have sufficient external validity to address the scope of the
decision problem [11, 12], whilst the third did not include
enough information to make a reliable judgement [20].
The key challenge of the economic evaluation related to
the variation in measurement and recording of baseline
CRBSI between hospitals. The sponsor utilised a rate of
1.48 CRBSI per 1000 catheter days within their economic
modelling. As described in Sect. 4.2.3, the EAC undertook
scenario and sensitivity analysis around this value. The
difficulties associated with measuring CRBSI and the
implications of this were captured in the final guideline.
The assessment process was aided by the good quality of
the sponsor’s submission, which included robust literature
searches for clinical evidence and model input parameter
values as well as robust economic modelling with proba-
bilistic analysis. Where possible, if not provided by the
sponsor, the EAC should undertake probabilistic sensitivity
analyses in order to capture uncertainty within the eco-
nomic modelling results. However, the benefits of under-
taking the analyses are dependent upon the information
available to inform confidence around input parameters.
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Where there is a paucity of evidence, the reliability of the
probabilistic analysis results will be compromised.
7 Conclusion
The MTEP evaluation process was followed for the
development of medical technologies guidance on Tega-
derm CHG. This included a submission of clinical and
economic evidence by the sponsor, critical appraisal of this
evidence by the EAC, additional work to address remaining
uncertainties, drafting of recommendations by the MTAC,
and a subsequent consultation. Following this process, the
MTAC judged that the evidence demonstrated sufficient
potential benefits of Tegaderm CHG to patients and the
NHS to allow positive recommendations to be made for the
dressing.
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